Cullen Frost Bankers Inc. Buys 3,450 Shares of Intuitive Surgical, Inc. $ISRG

Cullen Frost Bankers Inc. grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,056 shares of the medical equipment provider’s stock after purchasing an additional 3,450 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Intuitive Surgical were worth $36,698,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Intuitive Surgical by 6.8% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 11,802 shares of the medical equipment provider’s stock worth $5,278,000 after buying an additional 752 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Intuitive Surgical by 8.8% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 49,093 shares of the medical equipment provider’s stock worth $22,207,000 after purchasing an additional 3,964 shares during the last quarter. Whittier Trust Co. boosted its stake in Intuitive Surgical by 7.7% during the 3rd quarter. Whittier Trust Co. now owns 100,093 shares of the medical equipment provider’s stock valued at $45,277,000 after purchasing an additional 7,128 shares during the period. CIBC Asset Management Inc grew its holdings in Intuitive Surgical by 1.3% in the 3rd quarter. CIBC Asset Management Inc now owns 159,566 shares of the medical equipment provider’s stock valued at $71,363,000 after buying an additional 2,061 shares during the last quarter. Finally, Robocap Asset Management Ltd increased its position in Intuitive Surgical by 27.2% in the 3rd quarter. Robocap Asset Management Ltd now owns 14,542 shares of the medical equipment provider’s stock worth $6,504,000 after buying an additional 3,109 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near‑term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid‑teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating‑leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long‑term optionality: Early imaging data from the JURA feasibility study and a new 20 million‑patient da Vinci milestone reinforce long‑term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross‑margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross‑margin decline vs. recent quarters — a medium‑term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in‑line/hold (Evercore, Zacks), creating near‑term debate over valuation vs. growth and muting upside for traders focused on short‑term catalysts. The Fly: Evercore lowers price target

Wall Street Analysts Forecast Growth

ISRG has been the subject of several research reports. Truist Financial increased their target price on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. BTIG Research reissued a “buy” rating and issued a $616.00 target price on shares of Intuitive Surgical in a research note on Friday. Royal Bank Of Canada increased their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Leerink Partners lifted their price objective on Intuitive Surgical from $593.00 to $600.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Finally, HSBC upped their price objective on Intuitive Surgical from $595.00 to $644.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $617.57.

Insider Activity

In other news, SVP Mark Brosius sold 464 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the sale, the senior vice president directly owned 131 shares of the company’s stock, valued at $71,852.19. This represents a 77.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Craig H. Barratt sold 750 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $580.00, for a total transaction of $435,000.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 55,714 shares of company stock worth $31,617,799. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $523.99 on Friday. The company has a market cap of $187.84 billion, a price-to-earnings ratio of 66.41, a PEG ratio of 4.26 and a beta of 1.67. The stock has a fifty day moving average price of $562.32 and a two-hundred day moving average price of $511.68. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.18% and a net margin of 28.38%.The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same period last year, the company posted $2.21 earnings per share. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. As a group, research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.